



Iowa Department of Human Services

Terry E. Branstad
Governor

Kim Reynolds
Lt. Governor

Charles M. Palmer
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

December 3, 2014

**Location: Learning Resource Center
Fairmeadows Room
3550 Mills Civic Parkway
West Des Moines, Iowa**

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the Minutes
2. Commission Business
 - a) CMS Annual DUR Report – FFY13
 - b) State Annual DUR Report – SFY14
 - c) DHS Recommendation Letter – October 2014
 - d) Recommendation Letter to P & T – October 2014
3. IME Updates
4. Prevalence Report Summary
5. Case Studies
6. Public Comment (See Conflict of Interest Disclosure Form)
7. Focus Studies/Provider Education Initiatives
 - a) Three or more Antiepileptics with a Seizure Diagnosis – Follow Up
 - b) Three or more Antiepileptics without a Seizure Diagnosis – Follow Up
 - c) Memantine Utilization without a Valid Diagnosis – Follow Up
 - d) Duloxetine Dose Greater Than 120mg Per Day – Follow Up
 - e) High Dose Stimulants in Children – Initial Review
 - f) Benzodiazepine Dosing – Initial Review
8. Public Comment (See Conflict of Interest Disclosure Form)
9. Prior Authorization

- a) Hepatitis C Agents – Initial Review
- b) Deferasirox (Exjade[®]) – Initial Review
- c) Vorapaxar (Zontivity[™]) – Initial Review
- d) Ceritinib (Zykadia[™]) – Second Review

10. ProDUR Edit

- a) Antipsychotics – Age Edit and Duplicate Therapy Edit

11. Miscellaneous

- a) DUR Digest Vol. 27, No. 2 – Initial Review
- b) MedWatch
- c) New York Times Article – Cystic Fibrosis Foundation

<http://www.nytimes.com/2014/11/19/business/for-cystic-fibrosis-foundation-venture-yields-windfall-in-hope-and-cash.html>

12. Executive Closed Session

- a) Approval of Minutes
- b) Member Profiles

13. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Multiple representatives from a single organization will also be required to share the 5 minutes.

www.iadur.org

For more information contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting February 4, 2015***
at the West Des Moines Learning Resource Center
3550 Mills Civic Parkway, West Des Moines**